Canine Pipeline

Atopic Dermatitis in Dogs


Tirnovetmab (IL31 Antibody)
IL4R Antibody

Current market size is approx. $800M annually and growing

Prevalence

Itch is #1 reason for canine veterinarian visits

Diagnosis

10-15%

have atopic dermatitis, an allergic skin disease

Key Profit Center

83%

of dogs seen by dermatologists suffer from from pruritis (itch)

Growing Market

47%

increase in itchy dog veterinarian visits since 2014

KindredBio is pursuing a multi-pronged approach toward atopic dermatitis.

KindredBio reported positive topline results from its pilot field effectiveness study of tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs. We plan to begin a pivotal study in the fourth quarter of 2020.

We reported positive results from our pilot laboratory study of our interleukin-4R molecule, including evidence of positive efficacy and dose response. A second pilot study to further assess efficacy and dosing is planned for 3Q 2020.

The company reported positive results from its pilot efficacy study of its canine IL-4/13 SINK molecule in the first quarter of 2020. An initial pilot study for IL-17 has also been completed and the molecule was well-tolerated. Both programs are currently on hold pending further funding or partnering capital.

“Itch associated with Atopic Dermatitis may be caused by either neurogenic, inflammatory and/or behavioral pathomechanisms. I often find that I need to address a combination of pathways to successfully control itch in my atopic patients.”

- Tony Yu, BSc, DVM, MS ACVD

Learn More About:

KindredBio Investor Relations Atopic Dermatitis in Dogs

US-CORP-1900168 FEB-20

Canine Pipeline

Atopic Dermatitis in Dogs

News

Events